|
J Biol Chem, Vol. 273, Issue 36, 23134-23142, September 4, 1998
Identification and Characterization of the Structural and
Transporter Genes for, and the Chemical and Biological Properties
of, Sublancin 168, a Novel Lantibiotic Produced by Bacillus
subtilis 168*
Sun H.
Paik,
Anu
Chakicherla, and
J. Norman
Hansen
From the Department of Chemistry and Biochemistry, University of
Maryland, College Park, Maryland 20742
 |
ABSTRACT |
An antimicrobial peptide produced by
Bacillus subtilis 168 was isolated and characterized. It
was named sublancin 168, and its behavior during Edman sequence
analysis and its NMR spectrum suggested that sublancin is a
dehydroalanine-containing lantibiotic. A hybridization probe based on
the peptide sequence was used to clone the presublancin gene, which
encoded a 56-residue polypeptide consisting of a 19-residue leader
segment and a 37-residue mature segment. The mature segment contained
one serine, one threonine, and five cysteine residues. Alkylation of
mature sublancin showed no free sulfhydryl groups, suggesting that one
sulfydryl had formed a -methyllanthionine bridge with a
dehydrobutyrine derived by posttranslational modification of threonine;
with the other four cysteines forming two disulfide bridges. It is
unprecedented for a lantibiotic to contain a disulfide bridge. The
sublancin leader was similar to known type AII lantibiotics, containing
a double-glycine motif that is typically recognized by dual-function
transporters. A protein encoded immediately downstream from the
sublancin gene possessed features of a dual-function ABC transporter
with a proteolytic domain and an ATP-binding domain. The antimicrobial
activity spectrum of sublancin was like other lantibiotics, inhibiting
Gram-positive bacteria but not Gram-negative bacteria; and like the
lantibiotics nisin and subtilin in its ability to inhibit both
bacterial spore outgrowth and vegetative growth. Sublancin is an
extraordinarily stable lantibiotic, showing no degradation or
inactivation after being stored in aqueous solution at room temperature
for 2 years. The fact that sublancin is a natural product of B. subtilis 168, for which a great deal of genetic information is
available, including the entire sequence of its genome, suggests that
sublancin will be an especially good model for studying the potential
of lantibiotics as sources of novel biomaterials.
 |
INTRODUCTION |
Lantibiotics are bacterially produced antimicrobial peptides that
possess unique chemical and biological properties owing to their
containing a variety of unusual amino acid residues. Lantibiotics are
defined as such by the presence of lanthionine or
-methyllanthionine, which are introduced by a posttranslational process in which serine or threonine is dehydrated to the corresponding dehydro residue, which then reacts in a Michael-type addition of a
cysteine sulfhydryl group to the double bond of the dehydro residue to
form a thioether link (reviewed in Refs. 1-6). Mature lantibiotics
typically contain one or more dehydro residues that do not participate
in lanthionine bridges. The unique properties that are conferred by
these unusual residues may result in their being useful components in
the design of novel biomolecules (1, 2, 7, 8).
One of the attractive features of lantibiotics is that they are
comprised of gene-encoded polypeptide sequences, so their structures
can be manipulated by protein engineering. Whereas this is simple in
concept, putting it into practice requires the utilization of many
different genetic and recombinant DNA techniques, including the removal
and replacement of chromosomal segments with their genetically
engineered counterparts. Ideally, these manipulations need to be done
in such a way that the engineered lantibiotic analog be efficiently
produced so that useful amounts of the analog are available for
experimentation, which implies a need to engineer regulatory elements.
Only a few bacterial strains have been sufficiently characterized to
permit these manipulations to be performed in a convenient and facile
manner. One such well characterized bacterial strain is Bacillus
subtilis 168, which is second only to Escherichia coli
in the extent to which tools of genetic and protein engineering have
been developed, which has contributed to the extensive use of B. subtilis 168 for the industrial production of bio-engineered
materials. The advantage of B. subtilis 168 over other
bacterial strains has recently been increased even more by the
availability of the complete sequence of the B. subtilis 168 genome (9).
It is in this context that we report the discovery of a new
lantibiotic, which we have named sublancin 168, that is a natural product produced by B. subtilis 168. Although approximately
20 lantibiotics are already known, the fact that this new lantibiotic is endogenous to B. subtilis 168, and thus can be studied
and manipulated using the powerful methods that are available in this strain, suggests that progress in our understanding of lantibiotics will be accelerated by our ability to study and manipulate sublancin and the genes associated with its production in its natural B. subtilis 168 host. In addition to this practical aspect of the discovery, sublancin 168 has structural features and physical properties, such as the presence of disulfide bridges and extraordinary stability, that are unprecedented among the known lantibiotics.
 |
MATERIALS AND METHODS |
Bacterial Strains, Cloning Vectors, and Culture
Conditions--
Sublancin was isolated from B. subtilis
BR151, which is B. subtilis 168 (lys-3
metB10 trpC2), obtained from the Bacillus Genetics Stock
Center, Ohio State University, Columbus, OH. Stocks were maintained on
agar with Penassay broth (17.5 g of Bacto antibiotic medium 3/liter).
Sublancin was produced by inoculating 1 liter of medium A with 10 ml of
BR151 cultured for 16 h at 37 °C with vigorous aeration. Medium
A is as described previously (10, 11), except it contained 2% sucrose
instead of 10% sucrose. The culture was agitated vigorously by shaking
500-ml volumes at 200 rpm in 2-liter baffled flasks at 37 °C for
28 h, whereupon the culture usually acquired a pinkish-brown
color, a fruity odor, and a pH that had dropped to about 6. Good
sublancin production was consistently obtained when these events were
observed. For reasons that are not understood, the color, odor, and pH
changes did not always occur, whereupon sublancin production was
usually poor. Similar variability has been reported for subtilin
production in B. subtilis ATCC 6633 (10).
Isolation of Sublancin 168--
The culture was acidified to pH
2.5 with concentrated phosphoric acid, and centrifuged to remove cells.
The supernatant was made 1 M in NaCl and then applied, by a
peristaltic pump, to a hydrophobic interaction column constructed with
25 ml of Toyopearl® Butyl-650 resin (TosoHaas,
Montgomeryville, PA) that had been equilibrated with 1 M
NaCl, 50 mM NaAc, pH 4. Unbound proteins were eluted with
several volumes of the loading buffer, and the sublancin was eluted
with 50 mM NaAc, pH 4.0, or alternatively, with 30%
acetonitrile. After being lyophilized, the residue was dissolved in a
minimum amount of water that contained 0.1% trifluoroacetic acid,
centrifuged to remove particulates, and applied to an analytical reverse-phase C-18 HPLC1
column (Rainin/Varian, Walnut Creek, CA) in a Hewlett-Packard 1050 HPLC
machine with a diode-array detector. Sublancin was eluted using a
two-step gradient (solvent A was 0.1% trifluoroacetic acid in water,
solvent B was 0.1% trifluoroacetic acid in acetonitrile), the first
step going from 0 to 25% solvent B over 30 min, and the second step
going from 25 to 35% solvent B over 30 min, using a 1.2 ml/min flow
rate throughout. Fractions in the second step were assayed for
antimicrobial activity; active fractions were pooled, lyophilized, and
then subjected to a second round of HPLC purification using the same
conditions as the first round. The elution profile was monitored at
wavelengths of 214, 254, and 280 nm to detect the presence of peptide,
dehydro residues, and aromatic residues, respectively. During the
second round of HPLC purification, the activity was associated with a
single absorbance peak, which was lyophilized and stored at 20 °C.
Assay of Sublancin 168 Activity--
Two methods were employed:
a halo assay on plates, and a liquid assay in culture tubes. Both
methods used Bacillus cereus T spores as the test organism.
250 mg of spores, prepared as described previously (12), were suspended
in 30 ml of distilled water with a glass homogenizer, heat-shocked at
65 °C for 2 h, centrifuged, and resupended in 50% ethanol.
This suspension was sprayed onto the surface of medium A-containing
agar plates using a Sigma spray unit. Prior to spraying, 10-20-µl
volumes of serial dilutions of purified sublancin were spotted onto the
plate. The plates were incubated at 37 °C for 5-12 h to allow
germination and growth of the spores, the diameters of the halos caused
by sublancin inhibition were measured, and the minimum amount of
peptide that was required to give an observable halo was noted. For the
liquid assay, heat-shocked spores were suspended in sterile water to a
final concentration of 2 mg/ml, and then added to culture tubes containing 1% Bacto-tryptone, 0.1 M Tris-Pi,
pH 6.8. Prior to adding the spores, serial dilutions of sublancin were
added to the tubes. The final concentration of spores was 0.1 mg/ml.
The tubes were incubated at 37 °C for 3 h, using sufficient
shaking to keep the spores well suspended. The cultures were then
examined using phase-contrast microscopy to observe the extent to which the spores had undergone germination, outgrowth, and vegetative growth.
The amount of sublancin required to prevent the spores from proceeding
through outgrowth was noted.
Spectrum of Sublancin Antibiotic Activity--
The ability of
sublancin to inhibit growth of a variety of Gram-positive and
Gram-negative bacterial strains was assessed using an agar-diffusion
method, and for those strains that showed sensitivity to sublancin, a
minimum inhibitory concentration (MIC) was determined. For the agar
diffusion test, agar plates contained Difco brain heart infusion
(Listeria monocytogenes, Lactococcus lactis, Enterococcus
faecalis, Streptococcus pyrogenes) or Difco nutrient broth
(B. cereus T, Bacillus megaterium, B. subtilis, Staphylococcus aureus, Staphylococcus
epidermidis, Bordetella bronchiseptica, E. coli, Yersinia
enterocolitica). A 1000-fold dilution of exponential cultures of
the respective strains was made into molten top agar containing the
appropriate medium, which was poured onto the agar plates. After
solidification of the top agar, wells were made with an Ouchterlony
punch and filled with 20 µl (25 µg) of sublancin solution. The
plates were incubated for 24 h at 37 °C, and the diameters of
any halos of inhibition around the wells were measured. For those
strains that showed a halo of inhibition, a MIC was determined by
making a 100-fold dilution of an exponential culture of cells in tubes
containing growth medium together with different concentrations (5, 10, 25, 50, or 100 µg/ml) of sublancin, which were incubated with shaking at 37 °C for 18-30 h, until the respective control cultures without sublancin reached saturation. The MIC was that concentration of sublancin that completely suppressed growth of the cells.
Amino Acid Sequence and Composition Analysis--
Purified
sublancin was sequenced from its N-terminal end using Edman
degradation, using an Applied Biosystems (Foster City, CA) model 477A
peptide sequencer with an on-line HPLC analyzer in the University of
Maryland Core Facility (Baltimore, MD). Amino acid composition analysis
was performed on HCl hydrolysates by Commonwealth Biotechnologies, Inc.
(Richmond, VA). Sublancin was treated with ethanethiol in order to
sequence through any dehydro residues, which are otherwise blocked,
using the method of Meyer et al. (13). The modification
mixture consisted of 280 µl of ethanol, 200 µl of sterile deionized
water, 65 µl of 5 M NaOH, and 60 µl of ethanethiol. 150 µl of this modification mixture was added to 50 µg of freeze-dried
sublancin and incubated under nitrogen for 1 h at 50 °C. The pH
was lowered by addition of 5 µl of glacial acetic acid, and the
product purified by HPLC as described above for sublancin.
NMR and Mass Spectral Analysis--
One-dimensional NMR
spectroscopy was performed with a Bruker AMX-500 NMR spectrometer
interfaced to an Aspect 3000 computer using UXNMR software. Lyophilized
sublancin was dissolved in 99.96% atom% D2O to exchange
protons and lyophilized (done twice) and dissolved in D2O
to a final concentration of 10 mg/ml. The proton spectra were recorded
at constant 295 K in D2O with and without the suppression
of the water solvent resonance. Mass spectral analysis was performed by
PeptidoGenic Research & Co (Livermore, CA) on a Sciex API I
Electrospray mass spectrometer. The reported masses are those
calculated as the most probable values based on the different
m/z forms.
Cloning of the Sublancin Gene--
A B. subtilis 168 genomic library was constructed in bacteriophage using total
chromosomal DNA from strain BR151 grown in 50 ml of Penassay broth.
Cells were lysed with a mixture of lysozyme, sodium dodecyl sulfate,
and proteinase K; the DNA was recovered and deproteinized with
phenol-chloroform as described previously (11). The genomic DNA was
partially digested with Sau3AI to give random fragments in a
12-23-kb size range, which were cloned into LambdaGEM-12 partially
filled-in XhoI half-site arms obtained from Promega
(Madison, WI), which were then packaged into E. coli cells
using the protocol provided by the manufacturer. The library was
screened for the sublancin gene using synthetic DNA oligomers whose
sequences were chosen using the strategy of Lathe (14), based on the
16-residue N-terminal sequence of sublancin. Three single-sequence
48-mer probes were designed, each one with randomly chosen degenerate
bases, and the synthesis was performed by Ransom Hill Bioscience
(Ramona, CA). For those amino acid residues that appeared as
unidentifiable blanks in the sequence, inosines were placed in
the corresponding codons in the probes. The three probes were: probe 1, GGGTTGGGTAAAGCCCAAIIIGCGGCCTTGTGGTTACAGIIIGCTTCC; probe 2, GGGTTGGGCAAAGCACAGIIIGCGGCTTTTTGGTTACAGIIIGCGTGC; probe 3:
GGACTTGGTAAAGCGCAAIIIGCAGCTCTGTGGCTTCAAIIIGCATGC.
The probes were radiolabeled with 32P at their 5' ends
using T4 polynucleotide kinase and hybridized to Southern blots of
restriction digests of BR151 genomic DNA under a variety of temperature
and ionic strength conditions in order to optimize the signal strength and specificity. Probe 1 gave a good signal when hybridized at 45 °C
in 6× SSC and washed at 37 °C in 2× SSC, whereas probe 3 gave a
good signal when hybridized at 45 °C in 6× SSC and washed at
45 °C in 2× SSC. A good signal for probe 2 could not be obtained, so its use was abandoned. The bacteriophage library was plated and
transferred to duplicate nitrocellulose filters using standard procedures (15). One of the duplicate filters was hybridized to probe
1, and the other to probe 3. The only plaques selected for further
study were those that hybridized to both probes. Several such
dual-hybridizing plaques were picked, and their inserts were subcloned
into pTZ plasmids and screened again with probes 1 and 3. Positive
inserts were cloned into M13 and subjected to dideoxy sequence
analysis. The DNA sequences were conceptually translated into six
reading frames, which were searched for the N-terminal amino acid
sequence of sublancin. When the sublancin sequence was found, the
actual DNA sequence that encoded the sublancin gene could be
identified, which provided the sequence information needed to
synthesize probes that were exactly homologous to the sublancin gene.
These were used to identify library clones that contained sequences
that surrounded the subtilin gene, which were then also subcloned and
sequenced.
 |
RESULTS |
Isolation of Sublancin 168--
Our first observation of sublancin
was when it appeared as a contaminant in acetone-butanol extracts of
culture supernatants of B. subtilis LH45, which is a strain
of B. subtilis 168 that has been genetically engineered to
produce subtilin (16). When the acetone precipitate was dissolved in
water and analyzed by reversed-phase HPLC, a peak that contained
antimicrobial activity that emerged earlier than subtilin was observed.
Its early emergence indicated that it is more hydrophilic than
subtilin, but its appearance in the acetone precipitate suggested that
it had subtilin-like physical properties. Several characteristics of
the wild-type B. subtilis 168 strain from which LH45 had
been derived suggested that wild-type B. subtilis 168 harbors an endogenous
lantibiotic.2 The possibility
that this contaminating activity might be a new lantibiotic prompted
its isolation and characterization.
To obtain this putative lantibiotic, a strain of B. subtilis
168 was cultured as described under "Materials and Methods," and
the active material was recovered from the supernatant using a
hydrophobic interaction column and purified to near-homogeneity on a
reversed-phase HPLC column, as shown in Fig.
1. The active peak showed absorbances at
214, 254, and 280 nm; when the active peak was treated with ninhydrin,
it gave the purple color that is characteristic of proteins and
peptides. The antimicrobial substance was named sublancin 168, to
connote its being an antimicrobial peptide that is produced by
B. subtilis 168.

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 1.
HPLC purification of sublancin 168. Elution of sublancin from a reversed-phase C-18 column using a
water-trifluoroacetic acid-acetonitrile gradient as described under
"Materials and Mehtods." Profile shown is the second round of
purification, in which the activity eluted in the middle of the second
step of the gradient, which went from 25-35% acetonitrile over 30 min
at 1.2 ml/min. The molecular mass of the material eluting in the
activity peak was 3877.78 kDa.
|
|
Structure Analysis of Sublancin 168--
The sublancin peptide was
subjected to N-terminal sequence analysis using Edman degradation. It
gave a sequence of
Gly-Leu-Gly-Lys-Ala-Gln-Xaa-Ala-Ala-Leu-Trp-Leu-Gln-Xaa-Ala-Xaa-Xaa-Xaa. The blank cycles (Xaa) were those that did not show an
identifiable amino acid, some of which could be due to Cys residues,
which were underivatized and therefore not detectable. Other potential sources of blank cycles are the unusual amino acid residues typically found in lantibiotics. For example, lanthionine residues do not produce
peaks that are identifiable as normal amino acids, and the dehydro
residues block the sequence analysis because they spontaneously lose
their N-terminal amino group and are therefore unable to react with the
Edman reagent (17), thus bringing the sequence analysis to a halt. This
dehydro-residue block can be alleviated by reacting the peptide with
ethanethiol, which adds across the double bond, thus preventing loss of
the N-terminal amino group (13). Sublancin was accordingly derivatized
with ethanethiol, whereupon it was possible to sequence past the
apparent block at position 16, and to obtain Gly both at positions 17 and 18; however, a blank was then encountered at position 19. The fact
that ethanethiol derivatization alleviated the block at position 16 is
strong evidence that residue 16 is a dehydro residue.
Cloning and Sequence Analysis of the Sublancin Gene--
Since
lantibiotics are biosynthesized from gene-encoded precursors, one
approach to determine if sublancin is a lantibiotic is to see if it is
gene-encoded, and if it is, to examine the gene and the operon in which
it is found to see if they possess features that are characteristic of
lantibiotics. To determine whether sublancin is a gene-encoded peptide,
the N-terminal sequence was used to design a hybridization probe, which
was then used to screen a B. subtilis 168 genomic library
that had been constructed in bacteriophage . Clones containing
positive signals were subjected to DNA sequence analysis. The probe
design, screening, and sequencing are described under "Materials and
Methods." Nearly 5 kb of sequence was obtained, which we published in
a public data base as soon as it was complete (GenBank accession no.
AF014938 (1997)). This sequence was searched for open reading frames
(ORFs), which were in turn searched for the N-terminal amino acid
sequence of sublancin 168. A 56-residue ORF, shown in Fig.
2, that contained a perfect match to the
N-terminal sequence of the sublancin peptide was found near the center
of the 5-kb sequence. In addition, a 332-residue ORF was found upstream
from the sublancin gene, and about 560 residues of a partially complete
ORF was found downstream from the sublancin gene. The locations of
these three ORFs within the 5-kb sequence are shown in Fig. 2. Several
months after our sequence was published in GenBank, the Bacillus Genome
Project published the complete B. subtilis 168 genome (9),
which mapped these genes at a position of 193.8° on the B. subtilis 168 chromosome.

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 2.
Sequence of presublancin 168. The
conceptual translation of the 56-residue ORF in the middle of the 5-kb
sequence is shown, cleaved into a 19-residue leader segment, and a
37-residue mature segment. The N-terminal end of the mature segment is
a perfect match to the N-terminal amino acid sequence of the
HPLC-purified sublancin shown in Fig. 1. Serine, threonine, and
cysteine residues which are candidates for posttranslational
modification during maturation are shown in an enlarged
font. The uvrX gene encodes an ORF with homologies to
proteins involved in uv repair, and is therefore presumed to be
unrelated to sublancin biosynthesis. The sunA gene encodes
the presublancin polypeptide as indicated, followed by a non-coding
reagion, and then sunT gene, which encodes SunT, which is
the putative sublancin transporter as described in the text and in
Figs. 3 and 4. The direction of transcription of these genes is
indicated by the horizontal arrows. P indicates
the location of a consensus prokaryotic promoter site as described in
the legend of Fig. 3.
|
|
The putative functions of the upstream and downstream ORFs were
explored by searching the GenBank/EMBL nucleotide data bases for
homologies to proteins with known functions. The 332-residue upstream
ORF (denoted uvrX) showed extensive homologies to proteins involved in repair of uv damage to DNA, so a role in the biosynthetic pathway of sublancin seems unlikely. The 560-residue segment of the
downstream ORF showed homologies to known ABC transporter proteins
including PepT, which is the transporter that is responsible for
secretion of Pep5 during its biosynthesis (19). The gene for this
downstream ORF (denoted sunT) is therefore a strong
candidate as the corresponding transporter that participates in the
secretion of sublancin. Fig. 3 shows the
segment of the DNA sequence that contains the sublancin gene
(sunA), and the 5-prime end of sunT, together
with their conceptual translations (SunA and the N-terminal portion of
SunT), the putative promoter region of the sun operon, and
the ribosome binding site of the SunA mRNA. The complete sequences and their conceptual translations are available as accession number AF069294 in GenBank.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 3.
Nucleotide sequence of the sublancin
gene. The sublancin gene (sunA) and the 5'-end of the
sunT gene are shown, along with their conceptual
translations. Homologies of the N-terminal end of SunT to PepT and
LcnDR3, which are lantibiotic and dual-function transporters,
respectively, are shown in Fig. 5. The TATATT ( 10) and TTGAAT ( 35)
regions show strong homology to the consensus prokaryotic promoter
(35), and is the likely promoter of the sun operon. The
GGAGG identified as r.b.s. is a standard prokaryotic
consensus ribosome binding site that is appropriately located to be
functional. The sunT gene encodes an unusual UUG initiation
codon that can be identified by the purine-rich Shine-Dalgarno sequence
(18) that is underlined. This may result in the
sunT mRNA being translated less efficiently than the
sunA mRNA. The complete coding sequences of the
sunA and sunT genes and their conceptual
translations are available as Accession Number AF069294 in
GenBank.
|
|
If sublancin 168 is a lantibiotic, then SunA is presublancin, and
accordingly should contain structural features that are similar to
known prelantibiotics. Fig. 4 compares
presublancin with the type A lantibiotics, which are divided into two
subtypes, AI and AII. The type A lantibiotics include those that are
the most thoroughly studied, such as nisin A, subtilin, epidermin, and
Pep5. Type A lantibiotics are characterized by being elongated and
cationic with molecular masses ranging from 2151 to 4635 Da (1). The
mature region of the sublancin peptide is cationic, and its predicted
molecular mass is approximately 3900 Da (depending on what
posttranslational modifications have occurred), and thus possesses
characteristics of a type A lantibiotic. Type AI and type AII
lantibiotics differ in their leader segments, with the AII leaders
containing a GA/GS/GG ("double-glycine") sequence motif immediately
preceding the cleavage site, and conserved EL/EV and EL/EM sequences
upstream from the cleavage site. Double-glycine type leader peptides
are unrelated to the N-terminal sequences utilized by the
sec pathway, and the corresponding ABC transporters typically possess a dual function that both removes the leader peptide
and translocates it across the cytoplasmic membrane (20). These
features are shared by several non-lantibiotic antimicrobial peptides,
including pediocin and lactococcin A, which are produced by
Gram-positive bacteria; and by colicin V, which is produced by
Gram-negative E. coli (20), suggesting that the
double-glycine leader peptide may represent an evolutionary
branch-point between the lantibiotic and non-lantibiotic peptides.

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 4.
Alignment of pre-sublancin with type AI and
type AII pre-lantibiotics. Figure shows conserved leader segments
of AI and AII as identified by Nes and Tagg (3). Sublancin shows
homologies that are characteristic of type AII lantibiotics, including
the "diglycine motif" found in leaders that are normally cleaved by
dual-function transporters that contain a leader peptidase function
(20), as described under "Results."
|
|
If the double-glycine leader peptide of sublancin is cleaved by a
protease that is a component of a dual-function transporter, then the
transporter should contain an identifiable protease domain. Examination
of the ORF that is immediately downstream from the sunA gene
shows that the putative SunT protein shows such a protease domain. Fig.
5 compares SunT with two other
ABC-transporter proteins: PepT, which is the transporter for the type
AI lantibiotic Pep5 (which does not have a diglycine-type leader
peptide), and LcnDR3, which is the transporter for the non-lantibiotic
lactococcin DR (which does have a diglycine-type leader peptide). The
LcnDR3 protein contains an N-terminal protease domain that consistently appears in the dual-function transporters that cleave the leaders that
contain the diglycine motif (20), and this protease domain also appears
in the SunT protein, and contains the conserved cysteine and histidine
residues that are part of the active site of the proteolytic
domain.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 5.
Comparison of SunT to other bacteriocin
ABC-transporter proteins. The N-terminal end of SunT is compared
with the N-terminal end of LcnDR3, the lactococcin DR transporter (20),
and the N-terminal end of PepT, the ABC-transporter that exports the
lantibiotic Pep5 during biosynthesis (19). Pep5 is a type AI
lantibiotic (non-diglycine leader), and its transporter does not
possess a N-terminal proteolytic domain. However, the C-terminal
ATP-binding domain of PepT shows strong homology to SunT (not shown).
LcnDR3 does possess an N-terminal proteolytic domain, and a homologous
counterpart appears in SunT, including the conserved histidine and
cysteine regions (identified by enclosing boxes
and by stars) that are part of the active site of the
proteolytic domain (20). The GenBank accession numbers of SunT, LcnDR3
(also called LctT), and PepT are AF069294, U91581, and Z49865,
respectively.
|
|
The fact that the leader segment of sublancin contains that conserved
features that are typical of type AII lantibiotics constitutes evidence
that sublancin is not only a lantibiotic, but is a type AII
lantibiotic. The SunT protein supports this conclusion by showing the
presence of the protease domain that is expected for a transporter of a
type AII lantibiotic. Moreover, there is strong homology to PepT, which
is a transporter of the lantibiotic Pep5, and lantibiotic transporters
(LanT proteins) are generally conserved (2). All of these
considerations are consistent with sublancin's being a lantibiotic of
the AII type.
Biochemical Properties of Sublancin--
For sublancin to be a
typical lantibiotic, it should contain at least one lanthionine
residue, either Lan or MeLan; and at least one dehydro residue, either
Dha formed from serine, or Dhb formed from threonine. The putative
mature region of sublancin contains only one serine (residue 16), and
one threonine (residue 19). For sublancin to contain at least one
dehydro residue and one lanthionine residue would require that both the
Ser16 and Thr19 be converted to Dha and Dhb,
respectively, and for one of them to form a cross-linkage with a
cysteine, and for the other to remain as a dehydro residue. These
possibilities can be distinguished by NMR spectroscopy. Both Dha and
Dhb contain vinyl protons, which typically give resonance peaks in the
= 5.2-6.9 ppm region of the NMR spectrum, with Dha appearing as a
doublet, and Dhb appearing as a quartet (7, 21-23). The NMR spectrum
of sublancin is shown in Fig. 6. A
portion of the NMR spectrum shows a doublet appearing at 6.2 ppm,
which is in the middle of the vinyl proton region, and therefore argues
that a dehydro residue is present, and its being a doublet further
argues that it is a Dha. The other peaks are in the aromatic proton
region ( = 6.5-8.0), and can be attributed to the aromatic residues
in sublancin. It is to be noted that the Edman degradation of native
sublancin was blocked from residue 16 on, and this block was alleviated
by reacting with ethanethiol, which is also consistent with residue 16 being a dehydro residue. Since the gene sequence shows a Ser at
position 16, one can conclude that the Dha shown in the NMR spectrum is
derived by post-translational dehydration of Ser16 to
Dha.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 6.
Proton NMR specrum of sublancin 168. The
part of the spectrum that encompasses portions of the aromatic and
vinyl proton regions is shown. The doublet resonance centered at = 6.2 is identified as Dha16 for reasons described under
"Results." There were no other peaks in the vinyl proton region.
The peaks in the aromatic region are assumed to represent the aromatic
residues in sublancin.
|
|
When sublancin was subjected to SDS-PAGE, it showed a single band that
migrated at a position that corresponded to a molecular mass of
approximately 4 kDa (data not shown). Ion-spray mass spectroscopy provided a more precise molecular mass of 3877.78 kDa, as shown in Fig.
1. The sublancin molecular mass as predicted from the amino acid
sequence encoded in the sublancin gene is 3713.3 Da, assuming one
MeLan, one Dha, and four cysteines existing in two disulfide bridges.
There is thus a discrepancy of 164.48 Da between this predicted
molecular mass and the actual molecular mass, which may be due to one
or more additional modifications of the amino acids, as considered
under "Discussion."
Analysis of Disulfide Cross-linkages in Sublancin--
The
sublancin prepeptide contains five cysteine residues, which is the same
number of cysteines as are present in the prepeptides of nisin and
subtilin. However, in nisin, subtilin, and all other known
lantibiotics, all of the cysteine residues are converted to unusual
residues such as the five Lan and MeLan in nisin (24) and subtilin
(11), or the aminovinylcysteine in epidermin (25). For a natural
lantibiotic to contain unmodified cysteines or disulfide cross-linkages
is unprecedented, so the cysteine residues in sublancin were examined
to see if any possessed the characteristics of either free sulfhydryl
groups or disulfide bridges. The amino acid analysis that was employed
cannot detect free cysteine residues, but can detect them as
carboxymethyl-cysteine if they are alkylated prior to acid
hydrolysis. Alkylation of native sublancin followed by amino acid
analysis gave no detectable carboxymethyl-cysteine, which rules out the
presence of free sulfhydryl groups (data not shown). Reduction of
sublancin with dithiothreitol followed by alkylation gave 3.3 (suggesting a real value of 4, since the 3.3 is likely a minimum value,
and the nearest integer value larger than 3.3 is 4)
carboxymethyl-cysteines/mol of sublancin. SDS-PAGE and ion-spray mass
spectroscopy results described above established that sublancin exists
exclusively as a monomer, so there cannot be any intermolecular
disulfide bridges. These observations are all consistent with four of
the cysteines of sublancin participating in two disulfide bridges, with
the fifth cysteine having been converted to a MeLan residue by reacting
with a Dhb residue (derived from post-translational dehydration of
Thr19), leaving the unreacted Dha16 that is
revealed in the NMR spectrum.
The number and location of disulfide bridges was further explored by
analysis with proteolytic enzymes. The native form of sublancin, and
the denatured form, and the denatured-reduced form of sublancin were
all resistant to trypsin, despite the presence of a Lys at position 4 and an Arg at position 33. When the denatured and reduced sublancin was
alkylated, trypsin cleavage gave detectable amounts of fragments of
3200 and 1581 Da, neither of which is an expected product. Sublancin
was more sensitive to chymotrypsin, with even the native molecule being
substantially degraded, to give products of 1392 and 1823 Da. The first
is consistent with a polypeptide consisting of residues 1-11 being
cross-linked by a disulfide bridge to a peptide consisting of residues
36 and 37 (G1-W11-S-S-C36-R37,
with an expected value of 1392 Da), and the second is consistent with a
polypeptide consisting of residues 1-11 cross-linked by a disulfide
bridge to a peptide consisting of residues 33-37
(G1-W11-S-S-R33-R37,
with an expected value of 1, 823 Da); with chymotrypsin having cleaved
at typical major cleavage sites (Trp11, Tyr32,
Phe35). From this, we can conclude that native sublancin
has a disulfide bridge between Cys7 and Cys36.
To decide upon the location of the second disulfide bridge, we compare
sublancin to other type A lantibiotics, and note that formation of a
thioether link between Cys22 and Dhb19, to give
a Aba19-Ala22 MeLan-type cross-linkage would
put a two-residue Gly20-Gly21 sequence in the
ring enclosed by the MeLan cross-link, which is similar to the
two-residue Pro9-Gly10 sequence enclosed by the
Aba8-Ala11 MeLan cross-link in both nisin and
subtilin. Moreover, formation of this particular MeLan bond is
consistent with the observation that the Cys-dehydro partner selection
in lantibiotics consistently involves a dehydro residue that is on the
N-terminal side of the Cys residue. Assuming that the MeLan that
actually forms conforms to these standard patterns, then
Cys22 will react with Dhb19, which would
require the second disulfide bridge to form between Cys14
and Cys29, as shown in Fig.
7.

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 7.
The locations of thioether and disulfide
bridges in sublancin. The position of the lanthionine residue and
the pattern of disulfide bridge formation were inferred from the NMR
spectrum, N-terminal amino acid sequence analysis, amino acid
composition analysis, reaction with sulfhydryl-directed agents,
proteolytic digestions, and conserved features among lantibiotics as
described under "Results." The representation of the sublancin
structure as three open circles and a salt-bridge between
the N-terminal amino group and the C-terminal carboxyl group is
arbitrary, since no information about the secondary structure of
sublancin is available.
|
|
Spectrum of Antimicrobial Activity of Sublancin 168--
The
lantibiotic family of antimicrobial peptides shows broad spectrum
activity against Gram-positive bacteria, and very little activity
against Gram-negative bacteria (1, 2). To see if sublancin conforms to
this pattern, we tested the ability of sublancin to inhibit growth of
the battery of Gram-positive and Gram-negative bacterial species used
by Cleeland and Squires (26) to evaluate the spectrum of activity of
antimicrobial agents. As described under "Materials and Methods,"
the strains were first assayed for susceptibility to sublancin in an
agar-diffusion test. Next, the MIC for susceptible strains was
determined in liquid culture. The results in Table
I show that the antibiotic spectrum of
sublancin is consistent with its being a lantibiotic, in that
inhibition was observed only among Gram-positive strains of bacteria.
However, not all the tested strains of Gram-positive bacteria were
sensitive, and those that were sensitive varied considerably in their
sensitivity to sublancin. Whereas Bacillus megaterium 14581 and Bacillus subtilis 6633 were inhibited by 5 µg/ml
sublancin, Bacillus cereus T and Staphylococcus
aureus 12600 required more than 100 µg/ml for complete inhibition to occur.
View this table:
[in this window]
[in a new window]
|
Table I
Spectrum of activity of sublancin against exponentially growing
Gram-positive and Gram-negative strains of bacteria
Strains were obtained from the American Type Culture Collection (ATCC),
and the ATTCC strain numbers are indicated. Sensitivity to sublancin
was determined by the agar diffusion test, and the degree of
sensitivity was estimated from the diameter of the halo. ++++ indicates
a halo diameter >200 mm, +++ a diameter of 100-200 mm, + a diameter
<60 mm, and indicates no halo of inhibition. MIC values
indicate the concentrations of sublancin that gave complete inhibition
of cell growth in liquid culture.
|
|
Effect of Sublancin on Bacterial Spore Outgrowth--
The ability
of sublancin to inhibit bacterial spore outgrowth was also determined.
This is important, because it has been demonstrated that an intact
Dha5 residue in both subtilin (27) and nisin (28) is
required in order for inhibition of bacterial spore outgrowth to occur. The fact that an intact Dha5 residue is unnecessary to
inhibit exponentially growing cells established that the mechanism by
which subtilin and nisin inhibit spores is different than the mechanism
by which they inhibit growing cells (27). The ability of sublancin to
inhibit bacterial spore outgrowth was tested using the same methods as
for subtilin (27), which included a halo assay in which an agar plate
was sprayed with a suspension of B. cereus T spores, and
dilutions of sublancin were spotted onto the plate, which was incubated
to permit the spores to germinate, outgrow, and grow exponentially to
make a confluent lawn. Clear zones occur where the sublancin has been able to inhibit the development of spores into vegetative cells. The
other method was to incubate dilutions of sublancin with spores suspended in growth medium, and use phase-contrast microscopy to
observe the stage of inhibition. The latter method established that
sublancin permits the spores to germinate, to change from the
phase-bright dormant state to the germinated phase-dark stage; whereupon further development (swelling, elongation, emergence, division) are inhibited (data not shown). In this liquid assay, the
concentration of sublancin required to inhibit spore outgrowth was
about 0.1 µg/ml, (27 nM), which is significantly less
than the concentration of nisin (40 nM) or subtilin (80 nM) that is required to inhibit outgrowth of these same
spores (27, 29). It is notable that sublancin is about 1000-fold more
effective in inhibiting spore outgrowth than in inhibiting the same
cells in exponential growth. The corresponding ratio for subtilin is 30-fold, which means that, although sublancin is slightly better at
inhibiting spore outgrowth than is subtilin, subtilin is substantially better at killing the corresponding exponentially growing cells than is
sublancin. The requirement for an intact Dha5 residue in
nisin and subtilin in order to exhibit sporostatic activity suggests
that the Dha16 residue of sublancin may also play an
important role in the sporostatic processes, but this cannot be certain
without additional experiments.
While examining the halos caused by sublancin on the lawns of cells
produced by spraying the plate with spores, we noted a discrepancy
between the appearance of the halos produced by sublancin and the halos
produced by either nisin or subtilin (data not shown). With nisin and
subtilin, extended incubation of the plates for several days did not
result in any change in the size or appearance of the halos, which
remained completely clear. In contrast, incubation of the plates that
contained sublancin halos resulted in occasional colonies growing up in
within the halos, and a tendency for the surrounding cells to encroach
across the perimeter of the clear zone, to cause the size of the halo
to diminish slightly with time. The fact that the sublancin halos
diminished in size whereas the nisin and subtilin halos did not, is
explained by the relatively poor activity of sublancin against
vegetative B. cereus T cells, so once the spores had
developed into vegetative cells, they were able to encroach into the
halo. However, the appearance of colonies within the clear zone
suggested something else, which is that a small fraction of the spores
that had been inhibited by sublancin at the post-germination stage were
able to overcome this inhibition and proceed through outgrowth to the
vegetative stage. If so, this is in contrast to nisin or subtilin, both
of which have been shown to bind and inhibit spores irreversibly (30).
To determine whether sublancin binding and inhibition to germinated
spores is reversible, the B. cereus T spores were germinated
for 3 h in the presence of various concentrations of sublancin
ranging from 0.1 to 100 µg/ml, centrifuging the inhibited spores out
of the culture, and resuspending the spores in fresh medium without sublancin. The washed spores were then incubated for an additional 2-6
h and examined by phase-contrast microscopy. Whereas most of the spores
remained unchanged, a small percentage (about 1%) were clearly
proceeding through outgrowth, and eventually reached the vegetative
stage and proliferated. This result is consistent with the appearance
of colonies within the halos on the plates, where the colonies
represent those inhibited spores that recovered after the sublancin had
diffused away. The tendency of sublancin to dissociate from the spores
may be a consequence of its containing only a single dehydro residue
instead of the three that are present in nisin and subtilin, as is
considered under "Discussion." The concentration of sublancin used
to treat the spores prior to washing had no effect on the outcome of
the recovery experiment, with the 0.1 µg/ml treatment showing the
same effect as the 100 µg/ml treatment. This shows that the spore
sites to which the sublancin become associated are saturated at very
low levels of sublancin.
Stability of Sublancin 168--
Antimicrobial peptides that are
chemically stable are better suited for practical applications than are
unstable ones. The chemical stability of sublancin was therefore
assessed when it was an unpurified component of the culture
supernatant, and after it had been purified by HPLC chromatography.
Activity was assessed using the agar-plate halo assay against bacterial
spores. Culture supernatant stored at room temperature showed little
change in halo size during the first 4 days, but showed significant
loss after 1 week. Culture supernatants stored at either 4 °C or
20 °C showed no change in halo size after 6 months. HPLC-purified
sublancin was remarkably stable, and one sample was stored as a 10 mg/ml solution of sublancin in sterile D2O, pH 6.5, in an
NMR tube for 2 years (protected from light), after which its activity
remained undiminished and its NMR profile unchanged (data not shown).
Sublancin was stable to a wide range of pH values when either
phosphoric acid or ammonium acetate buffers were used to adjust the pH
of culture supernatants over a range of 1.5-9.5. The samples were assayed after incubating them for 2 h at 4 °C. The pH 9.5 halo was diminished slightly, but the halos produced by the lower pH samples
were unchanged. Finally, a sample of the culture supernatant that was
autoclaved for 3 min at 121 °C showed undiminished activity. These
stability characteristics resemble those of nisin, which is very stable
at low pH and can survive autoclaving at pH 2.5 without damage, but is
fairly unstable above pH 7 (31). However, the ability of sublancin to
survive in aqueous solution, at a pH that is nearly neutral, for 2 years without any apparent chemical or biological degradation shows
that it is a peptide whose intrinsic stability is extremely high. This
extraordinary stability may prove to be a useful characteristic,
perhaps enhancing the utility of sublancin in practical applications,
or as a model compound whose study may inspire strategies for enhancing
the stabilities of non-sublancin antimicrobial peptides.
 |
DISCUSSION |
The evidence that sublancin 168 is a lantibiotic is strong. The
presublancin gene sequence encodes a serine residue at position 16 of
the mature region, which can serve as the precursor to dehydroalanine. Sequential Edman degradation was blocked at position 16, which is
characteristic of dehydro residues. As has been demonstrated for
dehydro residues in other lantibiotics, the block was alleviated by
derivatization with ethanethiol. The NMR spectrum of sublancin showed a
doublet in the vinyl proton region of the spectrum, which is consistent
with the presence of a dehydroalanine. Sequence analysis of the
sublancin gene showed a leader segment with homologies to known type II
lantibiotics, including the "double-glycine" sequence motif
immediately preceding the cleavage site, indicating that it is probably
translocated by a dual-function ABC transporter that both translocates
the peptide and proteolytically cleaves the leader segment. The gene
immediately downstream from the sublancin gene confirms this, in that
it encodes a protein that is homologous to known dual-function
transporters, with an identifiable proteolytic domain in addition to a
transporter domain. Although the presublancin gene encodes five
cysteines, reaction of sublancin with an alkylating agent failed to
demonstrate the presence of a free sulfhydryl group, which is
consistent with at least one of the cysteines having reacted with a
dehydrobutyrine residue to form a -methyllanthionine bridge. The
spectrum of activity of sublancin is similar to other lantibiotics in
that it is active against a variety of Gram-positive bacteria and
inactive against Gram-negative bacteria. It also showed strong
inhibition of bacterial spore outgrowth in addition to inhibition of
exponentially growing cells, as is seen with both nisin and subtilin.
However, unlike nisin and subtilin, washing sublancin-inhibited spores
could cause a small percentage (about 1%) of them to proceed through
outgrowth and then grow vegetatively, suggesting that the inhibitory
effect of sublancin against spores is slightly reversible. For both
nisin and subtilin, it has been demonstrated that the mechanism of
inhibition of spore outgrowth is different from the inhibition of
vegetative growth, in that an intact dehydroalanine is required for
spore outgrowth inhibition, but not for vegetative growth inhibition.
The fact that sublancin contains only one dehydro residue compared with
the three dehydro residues in nisin and subtilin may account for
sublancin showing reversibility of inhibition of spore outgrowth,
whereas nisin and subtilin do not. It has been suggested that the
dehydro residue can react with a nucleophilic target (2, 27, 29), in
which case the larger number of possible attachment points of nisin and
subtilin could reduce the likelihood of dissociation and reversal of
inhibition, although this explanation is hypothetical.
With this report of the discovery and characterization of sublancin
168, the family of known lantibiotics increases in both size and scope,
and there are now over 20 known lantibiotics (2). A striking feature of
lantibiotics is their diversity in terms of structure, chemical
properties, and biological properties (1, 2). The defining
characteristic of lantibiotics is that they contain the unusual amino
acid lanthionine or -methyllanthionine, which are formed by
posttranslational dehydration of serine or threonine, respectively,
followed by a Michael-type nucleophilic addition of a cysteine
sulfhydryl across the double bond. Because of this mechanism, the
presence of the lanthionine requires that the cell possess the
machinery to dehydrate serines and/or threonines in addition to the
ability to form the thioether linkage. Reflecting this, all the
currently known lantibiotics possess at least one lanthionine and one
dehydro residue in the mature peptide, although there is little reason
to believe that exceptions to this are impossible. Especially notable
is that, prior to our discovery of sublancin, all the cysteine residues
in known lantibiotics had undergone posttranslational modifications,
and never existed as disulfide bridges or free sulfhydryl groups.
Sublancin breaks this trend in that only one of its five cysteines has
been posttranscriptionally modified, and the other four cysteines
instead participate in two disulfide bridges.
Lantibiotics can be considered as a subset of the prodigious number of
ribosomally synthesized antimicrobial peptides that have been
discovered recently, many of which are produced by eukaryotic organisms, such as the defensins and cecropins (1, 32). Mammalian and
insect defensins, tachyplesins, and plant thionins all tend to be
disulfide-rich, typically containing two or three disulfide bridges
within a peptide consisting of 30-40 amino acid residues (33). The
ubiquity and frequency of disulfide bridges argues an important role,
perhaps by their ability to impose conformational constraints on the
peptide and contribute to conformational and chemical stability.
Because the thioether of the lanthionine bridge contains one sulfur
atom instead of two, the lanthionine would be expected to be more
conformationally constrained than the disulfide. Moreover, the
lanthionine is insensitive to redox conditions, while the disulfide is
easily broken under mild reducing conditions. In view of the apparent
superiority of the lanthionine bridge in terms of conformational and
chemical stability, it is somewhat surprising that sublancin contains
one lanthionine and two disulfides, instead of the three lanthionines
and no disulfides that are found in other lantibiotics such as
subtilin, which is produced by B. subtilis ATCC 6633, and
nisin. The fact that sublancin possesses both types of linkages
suggests that having both types confers a selective advantage. It has
been observed that antimicrobial peptides represent a remarkable
example of convergent evolution, in which a wide variety of organism
types have evolved antimicrobial peptides of common function from very
different ancestral origins (33). Perhaps sublancin represents a
converging evolutionary branch-point between prokaryotic lantibiotics
and eukaryotic defensins, in which sublancin has taken advantage of
both types of linkages.
One aspect of the sublancin structure that this work does not resolve
is the reason why the molecular mass of sublancin, as determined by
ion-spray mass spectroscopy, is 164.48 Da greater than expected from
the amino acid composition. This is very likely due to an unidentified
posttranslational modification. A precedent for additional
posttranslations is seen in subtilin, which is partially succinylated
at the N-terminal end, and the extent to which this modification occurs
increases as the culture ages (8, 34). However, succinylation is not a
possible explanation of the molecular size discrepancy in the case of
sublancin for two reasons. One is that succinylation blocks the N
terminus against Edman degradation (8, 34), but sublancin is not
blocked. A second reason is that the succinyl group should increase the molecular mass by only 100 Da instead of 164.48 Da. Our results that
provided molecular masses of sublancin fragments after chymotrypsin degradation establish that the modification must occur at a residue that lies between Trp11 and Arg33, because the
disulfide cross-linked chymotryptic fragment consisting of
(G1-W11-S-S-R33-R37)
has a molecular mass that is exactly that predicted from the amino acid
composition. The molecular mass discrepancy therefore must come from
the modification of one (or more) of the residues that resides outside
this fragment.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grant AI24454 and by AMBI, Inc. (Tarrytown, NY).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF069294.
To whom correspondence should be addressed. Tel.: 301-405-1847;
Fax: 301-314-9121; E-mail: jh21{at}umail.umd.edu.
The abbreviations used are:
HPLC, high
performance liquid chromatography; ORF, open reading frame; MIC, minimum inhibitory concentration; PAGE, polyacrylamide gel
electrophoresis.
2
A. Chakicherla and J. N. Hansen,
unpublished observations.
 |
REFERENCES |
-
Hansen, J. N.
(1993)
Annu. Rev. Microbiol.
47,
535-564[CrossRef][Medline]
[Order article via Infotrieve]
-
Hansen, J. N.
(1997)
in
Bio/Technology of Antibiotics (Strohl, W. R., ed), 2nd Ed., pp. 437-470, Marcell Dekker, Inc., New York
-
Nes, I. F.,
and Tagg, J. R.
(1996)
Antonie Van Leeuwenhoek
69,
89-97[CrossRef][Medline]
[Order article via Infotrieve]
-
Sahl, H.-G.
(1994)
Ciba Found. Symp.
186,
27-53[Medline]
[Order article via Infotrieve]
-
Sahl, H. G.,
Jack, R. W.,
and Bierbaum, G.
(1995)
Eur. J. Biochem.
230,
827-853[Medline]
[Order article via Infotrieve]
-
de Vos, W. M.,
Kuipers, O. P.,
Vandermeer, J. R.,
and Siezen, R. J.
(1995)
Mol. Microbiol.
17,
427-437[Medline]
[Order article via Infotrieve]
-
Liu, W.,
and Hansen, J. N.
(1992)
J. Biol. Chem.
267,
25078-25085[Abstract/Free Full Text]
-
Chakicherla, A.,
and Hansen, J. N.
(1995)
J. Biol. Chem.
270,
23533-23539[Abstract/Free Full Text]
-
Kunst, F.,
Ogasawara, N.,
Moszer, I.,
Albertini, A. M.,
Alloni, G.,
Azevedo, V.,
Bertero, M. G.,
Bessieres, P.,
Bolotin, A.,
Borchert, S.,
Borriss, R.,
Boursier, L.,
Brans, A.,
Braun, M.,
Brignell, S. C.,
Bron, S.,
Brouillet, S.,
Bruschi, C. V.,
Caldwell, B.,
Capuano, V.,
Carter, N. M.,
Choi, S. K.,
Codani, J. J.,
Connerton, I. F.,
Danchin, A.,
et al..
(1997)
Nature
390,
249-256[CrossRef][Medline]
[Order article via Infotrieve]
-
Feeney, R. E.,
Garibaldi, J. A.,
and Humphreys, E. M.
(1948)
Arch. Biochem. Biophys.
17,
435-445
-
Banerjee, S.,
and Hansen, J. N.
(1988)
J. Biol. Chem.
263,
9508-9514[Abstract/Free Full Text]
-
Vary, J. C.,
and Halvorson, H. O.
(1965)
J. Bacteriol.
89,
1340-1347[Abstract/Free Full Text]
-
Meyer, H. E.,
Heber, M.,
Eisermann, B.,
Korte, H.,
Metzger, J. W.,
and Jung, G.
(1994)
Anal. Biochem.
223,
185-190[CrossRef][Medline]
[Order article via Infotrieve]
-
Lathe, R.
(1985)
J. Mol. Biol.
183,
1-12[CrossRef][Medline]
[Order article via Infotrieve]
-
Maniatis, T.,
Fritsch, E. F.,
and Sambrook, J.
(1982)
Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
-
Liu, W.,
and Hansen, J. N.
(1991)
J. Bacteriol.
173,
7387-7390[Abstract/Free Full Text]
-
Wakamiya, T.,
Ueki, Y.,
Shiba, T.,
Kido, Y.,
and Motoki, Y.
(1985)
Tetrahedron Lett.
26,
665-668[CrossRef]
-
Kozak, M.
(1983)
Microbiol. Rev.
47,
1-45[Free Full Text]
-
Meyer, C.,
Bierbaum, G.,
Heidrich, C.,
Reis, M.,
Suling, J.,
Iglesias-Wind, M. I.,
Kempter, C.,
Molitor, E.,
and Sahl, H.-G.
(1995)
Eur. J. Biochem.
232,
478-489[Medline]
[Order article via Infotrieve]
-
Havarstein, L. S.,
Diep, D. B.,
and Nes, I. F.
(1995)
Mol. Microbiol.
16,
229-240[Medline]
[Order article via Infotrieve]
-
Fisk, C. L.
(1975)
A Nuclear Magnetic Resonance Study of the Polypeptide, Nisin, Its Fragments and
, -Unsaturated Amino Acid Constituents.Ph.D. thesis, Georgetown University, Washington, D. C -
Jones, A. J.,
Helmerhorst, E.,
and Stokes, G. B.
(1983)
Biochem. J.
211,
499-502[Medline]
[Order article via Infotrieve]
-
Asquith, R. S.,
and Carthew, P.
(1972)
Tetrahedron
28,
4769-4773[CrossRef]
-
Buchman, G. W.,
Banerjee, S.,
and Hansen, J. N.
(1988)
J. Biol. Chem.
263,
16260-16266[Abstract/Free Full Text]
-
Kupke, T.,
Stevanovic, S.,
Sahl, H. G.,
and Gotz, F.
(1992)
J. Bacteriol.
174,
5354-5361[Abstract/Free Full Text]
-
Cleeland, R.,
and Squires, E.
(1991)
in
Antibiotics in Laboratory Medicine (Lorian, V., ed), pp. 739-786, Williams & Wilkins, Baltimore, MD
-
Liu, W.,
and Hansen, J. N.
(1993)
Appl. Environ. Microbiol.
59,
648-651[Abstract/Free Full Text]
-
Chan, W. C.,
Dodd, H. M.,
Horn, N.,
Maclean, K.,
Lian, L. Y.,
Bycroft, B. W.,
Gasson, M. J.,
and Roberts, G. C.
(1996)
Appl. Environ. Microbiol.
62,
2966-2969[Abstract]
-
Morris, S. L.,
Walsh, R. C.,
and Hansen, J. N.
(1984)
J. Biol. Chem.
259,
13590-13594[Abstract/Free Full Text]
-
Buchman, G. W. (1988) Ph.D. thesis, University of Maryland,
College Park, MD
-
Liu, W.,
and Hansen, J. N.
(1990)
Appl. Environ. Microbiol.
56,
2551-2558[Abstract/Free Full Text]
-
Hancock, R.
(1997)
Lancet
349,
418-422[CrossRef][Medline]
[Order article via Infotrieve]
-
Hancock, R.,
and Falla, T. J.
(1997)
in
Bio/Technology of Antibiotics (Strohl, W. R., ed), 2nd Ed., pp. 471-496, Marcel Dekker, Inc., New York
-
Chan, W. C.,
Bycroft, B. W.,
Leyland, M. L.,
Lian, L. Y.,
and Roberts, G. C.
(1993)
Biochem. J.
291,
23-27
-
Rosenberg, M.,
and Court, D.
(1979)
Annu. Rev. Genet.
13,
319-353[CrossRef][Medline]
[Order article via Infotrieve]
Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
Y. Luo and J. D. Helmann
Extracytoplasmic Function {sigma} Factors with Overlapping Promoter Specificity Regulate Sublancin Production in Bacillus subtilis
J. Bacteriol.,
August 1, 2009;
191(15):
4951 - 4958.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Liu, J. Zhong, J. Ni, M. Chen, H. Xiao, and L. Huan
Characteristics of the bovicin HJ50 gene cluster in Streptococcus bovis HJ50
Microbiology,
February 1, 2009;
155(2):
584 - 593.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-Y. F. Dubois, T. R. H. M. Kouwen, A. K. C. Schurich, C. R. Reis, H. T. Ensing, E. N. Trip, J. C. Zweers, and J. M. van Dijl
Immunity to the Bacteriocin Sublancin 168 Is Determined by the SunI (YolF) Protein of Bacillus subtilis
Antimicrob. Agents Chemother.,
February 1, 2009;
53(2):
651 - 661.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. M. Gut, A. M. Prouty, J. D. Ballard, W. A. van der Donk, and S. R. Blanke
Inhibition of Bacillus anthracis Spore Outgrowth by Nisin
Antimicrob. Agents Chemother.,
December 1, 2008;
52(12):
4281 - 4288.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Defoor, M.-B. Kryger, and J. Martinussen
The orotate transporter encoded by oroP from Lactococcus lactis is required for orotate utilization and has utility as a food-grade selectable marker
Microbiology,
November 1, 2007;
153(11):
3645 - 3659.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Strauch, B. G. Bobay, J. Cavanagh, F. Yao, A. Wilson, and Y. Le Breton
Abh and AbrB Control of Bacillus subtilis Antimicrobial Gene Expression
J. Bacteriol.,
November 1, 2007;
189(21):
7720 - 7732.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. L. McClerren, L. E. Cooper, C. Quan, P. M. Thomas, N. L. Kelleher, and W. A. van der Donk
Discovery and in vitro biosynthesis of haloduracin, a two-component lantibiotic
PNAS,
November 14, 2006;
103(46):
17243 - 17248.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. de Jong, S. A. F. T. van Hijum, J. J. E. Bijlsma, J. Kok, and O. P. Kuipers
BAGEL: a web-based bacteriocin genome mining tool.
Nucleic Acids Res.,
July 1, 2006;
34(Web Server issue):
W273 - W279.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Leclere, M. Bechet, A. Adam, J.-S. Guez, B. Wathelet, M. Ongena, P. Thonart, F. Gancel, M. Chollet-Imbert, and P. Jacques
Mycosubtilin Overproduction by Bacillus subtilis BBG100 Enhances the Organism's Antagonistic and Biocontrol Activities
Appl. Envir. Microbiol.,
August 1, 2005;
71(8):
4577 - 4584.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Albano, W. K. Smits, L. T. Y. Ho, B. Kraigher, I. Mandic-Mulec, O. P. Kuipers, and D. Dubnau
The Rok Protein of Bacillus subtilis Represses Genes for Cell Surface and Extracellular Functions
J. Bacteriol.,
March 15, 2005;
187(6):
2010 - 2019.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Tjalsma, H. Antelmann, J. D.H. Jongbloed, P. G. Braun, E. Darmon, R. Dorenbos, J.-Y. F. Dubois, H. Westers, G. Zanen, W. J. Quax, et al.
Proteomics of Protein Secretion by Bacillus subtilis: Separating the "Secrets" of the Secretome
Microbiol. Mol. Biol. Rev.,
June 1, 2004;
68(2):
207 - 233.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Dirix, P. Monsieurs, K. Marchal, J. Vanderleyden, and J. Michiels
Screening genomes of Gram-positive bacteria for double-glycine-motif-containing peptides
Microbiology,
May 1, 2004;
150(5):
1121 - 1126.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Xiao, X. Chen, M. Chen, S. Tang, X. Zhao, and L. Huan
Bovicin HJ50, a novel lantibiotic produced by Streptococcus bovis HJ50
Microbiology,
January 1, 2004;
150(1):
103 - 108.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. E. MacConaill, G. F. Fitzgerald, and D. van Sinderen
Investigation of Protein Export in Bifidobacterium breve UCC2003
Appl. Envir. Microbiol.,
December 1, 2003;
69(12):
6994 - 7001.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. G. Bermudez-Humaran, P. Langella, N. G. Cortes-Perez, A. Gruss, R. S. Tamez-Guerra, S. C. Oliveira, O. S. Cardenas, R. Montes de Oca-Luna, and Y. Le Loir
Intranasal Immunization with Recombinant Lactococcus lactis Secreting Murine Interleukin-12 Enhances Antigen-Specific Th1 Cytokine Production
Infect. Immun.,
April 1, 2003;
71(4):
1887 - 1896.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
T. Inaoka, K. Takahashi, M. Ohnishi-Kameyama, M. Yoshida, and K. Ochi
Guanine Nucleotides Guanosine 5'-Diphosphate 3'-Diphosphate and GTP Co-operatively Regulate the Production of an Antibiotic Bacilysin in Bacillus subtilis
J. Biol. Chem.,
January 17, 2003;
278(4):
2169 - 2176.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Dorenbos, T. Stein, J. Kabel, C. Bruand, A. Bolhuis, S. Bron, W. J. Quax, and J. M. van Dijl
Thiol-Disulfide Oxidoreductases Are Essential for the Production of the Lantibiotic Sublancin 168
J. Biol. Chem.,
May 3, 2002;
277(19):
16682 - 16688.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Stein, S. Borchert, B. Conrad, J. Feesche, B. Hofemeister, J. Hofemeister, and K.-D. Entian
Two Different Lantibiotic-Like Peptides Originate from the Ericin Gene Cluster of Bacillus subtilis A1/3
J. Bacteriol.,
March 15, 2002;
184(6):
1703 - 1711.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. S. Erlendsson and L. Hederstedt
Mutations in the Thiol-Disulfide Oxidoreductases BdbC and BdbD Can Suppress Cytochrome c Deficiency of CcdA-Defective Bacillus subtilis Cells
J. Bacteriol.,
March 1, 2002;
184(5):
1423 - 1429.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Tamehiro, Y. Okamoto-Hosoya, S. Okamoto, M. Ubukata, M. Hamada, H. Naganawa, and K. Ochi
Bacilysocin, a Novel Phospholipid Antibiotic Produced by Bacillus subtilis 168
Antimicrob. Agents Chemother.,
February 1, 2002;
46(2):
315 - 320.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Holo, Z. Jeknic, M. Daeschel, S. Stevanovic, and I. F. Nes
Plantaricin W from Lactobacillus plantarum belongs to a new family of two-peptide lantibiotics
Microbiology,
March 1, 2001;
147(3):
643 - 651.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
H. Tjalsma, A. Bolhuis, J. D. H. Jongbloed, S. Bron, and J. M. van Dijl
Signal Peptide-Dependent Protein Transport in Bacillus subtilis: a Genome-Based Survey of the Secretome
Microbiol. Mol. Biol. Rev.,
September 1, 2000;
64(3):
515 - 547.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. W. Ye, W. Tao, L. Bedzyk, T. Young, M. Chen, and L. Li
Global Gene Expression Profiles of Bacillus subtilis Grown under Anaerobic Conditions
J. Bacteriol.,
August 15, 2000;
182(16):
4458 - 4465.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
K. Altena, A. Guder, C. Cramer, and G. Bierbaum
Biosynthesis of the Lantibiotic Mersacidin: Organization of a Type B Lantibiotic Gene Cluster
Appl. Envir. Microbiol.,
June 1, 2000;
66(6):
2565 - 2571.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
A. Bolhuis, G. Venema, W. J. Quax, S. Bron, and J. M. van Dijl
Functional Analysis of Paralogous Thiol-disulfide Oxidoreductases in Bacillus subtilis
J. Biol. Chem.,
August 27, 1999;
274(35):
24531 - 24538.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1998 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|